Hemoglobin data

Time-Resolved Absorption Spectroscopy Advantages, 232, 389 applications, 232, 387-388 detectors, 232, 387, 392-393, 399 hemoglobin data analysis, 232, 401-415 kinetic analyses, 232, 390 photoselection effects, 232, 390-391 kinetic intermediates and. 

Fig. 20. Temperature dependence of the electron transfer rate, kt, in the [aFe(III) p Zn] hybrid hemoglobin. Data taken from ref. 91.

Fig. 19. The effect of KCl on the iaoionic pH of three proteins. The serum albumin data are from Scatchard and Black (1949), the hemoglobin data from Nozaki (1959), the /3-lactoglobulin data from Nozaki et al. (1959).

Fig. 12. Possible shapes and degree pf hydration of various protein molecules as deduced from various physical measurements. Compare the contour charts, Figures 1 and 2. From Oncley, Chapter 22 in reference 16, page 562. The horizontal bar in the figure for hemoglobin [data from X-ray studies) should be shifted downwards to lie tetween ajb = 1 and ajb = (see reference (6), and p. 136 of this review],...

F ure 2. Electron paramagnetic resonance spectra ofDMPO spin adducts in the reaction systems of ROOM plus met hemoglobin. Data were reproduced from references 8 and 18. 

Two sets of samples have been analyzed on one plate with a standard mixture of the hemoglobins C, S, A, and F occupying the fourth position from the ton. The data show that the hemoglobins A, F, S, and C are readily separated that the hemoglobins E and Dp do not separate from Hb-A and that some p-chain variants can readily be separated from Hb-F, Hb-A, Hb-S. or Hb-C (examples are the unidentified Hb-J, Hb-Fort Gordon (see also Figure 14), and Hb-O-Arab). 

Hematological and Hemoglobin Stability Data on 22 Members of the Family with Hb-Atlanta... 

Patients and clinicians can evaluate blood glucose control through a combination of self-monitoring of blood glucose data and hemoglobin HbAlc testing. 

The National Comprehensive Cancer Network (NCCN) recommends an anemia work-up for patients with hemoglobin of less than 11 g/dL (110 g/L or 6.8 mmol/L). Patients who are symptomatic or asymptomatic with significant risk factors (e.g., extensive transfusion history, myelosuppressive chemotherapy, etc) may qualify for treatment with erythropoietic agents such as epoetin-alfa or darbepoetin. Data do not support the use of one agent over another they are both equally effective in treating this type of anemia.12 Table 63-4 provides dosing recommendations for chemotherapy-related anemia. 

To date, three pharmaceutical companies have entered clinical trials with PHD inhibitors for the treatment of anemia with the most advanced being FG-2216. In clinical studies, compound 2 (likely FG-2216) showed a dose- and time-dependent elevation of plasma erythropoietin after oral administration [66]. Healthy volunteers were orally administered various doses of compound 2 and serum erythropoietin (EPO) concentrations were measured at various times. Compound 2 increased serum EPO levels in a dose-dependent manner and, following administration of the 20 mg/kg dose, a 5-fold increase of EPO levels was observed after 12 h. In the same patent application, the effect of 2 on anemic predialysis patients with no previous rh-EPO exposure was also disclosed. Patients were treated with 2 three times/week for 4 weeks (no dose reported) and the hemoglobin levels were assessed on day 42. The patients who received treatment showed a mean increase in hemoglobin of 1.9 g/dL from baseline values, whereas subjects who received placebo showed a mean decrease of 0.35 g/dL from baseline levels. These data suggest for the first time that an oral PHD inhibitor could be effective for the treatment of anemia. 

---